CD137 in chronic graft-versus-host disease

Area of Science:

• Immunology
• Transplantation Biology

Background:

• Chronic graft-versus-host disease (GVHD) is a frequent complication following allogeneic hematopoietic stem cell transplantation.
• Preclinical models are essential for understanding the mechanisms underlying chronic GVHD.

Purpose of the Study:

• To describe established preclinical animal models for chronic GVHD.
• To evaluate the efficacy of CD137 agonists in preventing and treating chronic GVHD.

Main Methods:

• Utilized DBA/2 → (C56BL/6 × DBA/2)F1 (BDF1) model exhibiting a systemic lupus erythematosus (SLE)-like phenotype.
• Employed B10.D2 → Balb/c model displaying autoimmune scleroderma features.
• Administered a single dose of CD137 agonists to assess therapeutic potential.

Main Results:

• The BDF1 model elucidates how alloreactive CD4(+) T cells disrupt B-cell tolerance.
• The Balb/c model aids in dissecting the pathogenesis of organ fibrosis in chronic GVHD.
• A single dose of CD137 agonists demonstrated efficacy in preventing and curing chronic GVHD in both models.

Conclusions:

• Preclinical chronic GVHD models are valuable for studying disease pathogenesis and screening immunomodulatory therapeutics.
• CD137 agonists represent a promising therapeutic strategy for managing chronic GVHD.